Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adsorbed Tetanus Vaccine Phase I/III Trial in Healthy Adults
CTR20232830Phase 3Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tetanus toxoid in Tetanus and influenza (2 arms), sponsored by Sinovac Biotech Ltd. Primary endpoints: Phase I: Adverse reaction rate within 0–7 days after vaccination, Phase I: Adverse reaction rate within 0–30 days after vaccination and 2 more. Started Sep 2023; status: completed.
02
Drugs
tetanus toxoid
03
Conditions
Tetanusinfluenza
Beyond the preview
Go deeper on CTR20232830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232830.